Genetic Analysis AS is a pioneering science-based diagnostic company specializing in the field of human microbiome research and product development. With over 10 years of expertise, we are committed to unlocking and restoring the human microbiome through our state-of-the-art technology. Our unique GA-map® platform utilizes a specialized pre-targeted multiplex approach, allowing for the simultaneous analysis of a large number of bacteria in one reaction.

With our clinically validated cutting-edge GA-map® software algorithm, we can provide immediate test results without the need for further bioinformatics work. Our core competence lies in the detection of microorganisms such as bacteria and viruses in stool samples, enabling us to develop In Vitro Diagnostic tests for various diseases involving the microbiota. Notably, we are the first company to develop, clinically validate, and commercialize a CE-marked In Vitro Diagnostic test, the GA-map® Dysbiosis Test Lx, used for diagnosing and characterizing dysbiosis in IBS and IBD patients.

In addition, we have recently launched the GA-map® COVID-19 fecal test, a Qualitative Real-Time PCR test that detects SARS-CoV-2 RNA in stool samples. This CE-marked test provides a valuable tool in the fight against the COVID-19 pandemic. With a team of highly qualified employees and expertise in bioinformatics, molecular biology, and bioengineering, Genetic Analysis AS strives to become the leading company for standardized gut microbiota testing worldwide.

To learn more about our products, services, and how we work, please visit our website or contact us directly